Results 41 to 50 of about 841 (115)

Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed [PDF]

Cancer continues to present a substantial global health challenge, with its incidence and mortality rates persistently reflecting its significant impact.
Diana E. Jaalouk, Karim Kanbar, Karim Kanbar, Roy El Darzi, Roy El Darzi   +4 more
core   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source

Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy

Journal of Nanobiotechnology
Epigenetic regulation has emerged as a promising therapeutic strategy for lung cancer treatment, which can facilitate the antitumor responses by modulating epigenetic dysregulation of target proteins in lung cancer. The proteolysis-targeting chimera (PROTAC) reagent, dBET6 shows effective inhibition of bromodomain-containing protein 4 (BRD4) that ...
Xiaoling Guan, Xiaowei Xu, Yiwen Tao, Xiaohua Deng, Linlong He, Zhongxiao Lin, Jishuo Chang, Jionghua Huang, Dazhi Zhou, Xiyong Yu, Minyan Wei, Lingmin Zhang   +11 more
openaire   +3 more sources

Mitophagy and Ubiquitination Coordinate Context‐Specific Mitochondrial Quality Control and EMT/MET Plasticity to Drive Cancer Cell Invasion

Advanced Science, Volume 13, Issue 16, 18 March 2026.
Metastatic invasion emerges when tumor‐intrinsic programs and microenvironmental forces converge on mitochondrial quality control. A context‐stratified framework links mtROS, mtDNA integrity, mechanics and nutrient/oxygen cues to fission–fusion remodeling, mtUPR and mitophagy.
Bin‐Hsu Mao, Bo‐Kai Su, Ying‐Jan Wang, Ting‐Yuan Tu   +3 more
wiley   +1 more source

PROTAC‑Mediated HMGCR Depletion Reprograms Lipid Metabolism in Breast Cancer to Potentiate Photoimmunotherapy via Ferroptosis

Advanced Science, Volume 13, Issue 13, 3 March 2026.
This work introduces a study that identifies HMGCR as a novel target in TNBC and develops a light‐gated PROTAC nanomedicine. Upon irradiation, this agent selectively degrades HMGCR, reprogramming lipid metabolism to induce ferroptosis and potent antitumor immunity, thereby significantly enhancing photoimmunotherapy efficacy.
Tong Su, Guang Li, Yudong Guan, Qi Tian, Youzhi Qi, Yanqiu Zhang, Wenqian Wei, Xinxin Duan, Jiaxin Rui, Hongyan Zhu, Zengping Lin, Changchuan Xie, Zheni Xu, Yaying Wu, Xin Peng, Zhenjie Wang, Kun Chen, Xiaoyan Xin, Bing Zhang   +18 more
wiley   +1 more source

The multifaceted roles of the ACSL family in cancer: Metabolic reprogramming, ferroptosis regulation and tumour immune microenvironment remodelling

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
The acyl‐CoA synthetase long‐chain (ACSL) family consists of five members, which exhibit a synergistic effect in promoting tumour lipid metabolism for energy supply. Specifically, ACSL3 and ACSL4 have antagonistic effects on the mechanisms related to ferroptosis in tumour cells.
Haocai Li, Weijian Wang, Juncheng Zhan, Yuxiang Xiao, Xiaoping Chen, Chen Su, Peng Zhu   +6 more
wiley   +1 more source

Preparation and Characterization of Ternary Complexes to Improve the Solubility and Dissolution Performance of a Proteolysis-Targeting Chimera Drug

Pharmaceutics
Background/Objectives: Proteolysis-targeting chimeras (PROTACs) have shown significant potential in the treatment of intractable diseases. However, their clinical applications are limited by poor water solubility and permeability.
Heng Zhang, Hengqian Wu, Lili Wang, Laura Machín Galarza, Chuanyu Wu, Mingzhong Li, Zhengping Wang, Erpeng Zhou, Jun Han   +8 more
doaj   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source

Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Molecular glue degraders (MGDs) constitute an emerging class of therapeutic agents poised to revolutionize the paradigm of targeted drug discovery. By reprogramming E3 ubiquitin ligases to degrade proteins of interest (POI) via a transient formation of a ternary complex mediated by protein–protein interactions, MGDs surpass the intrinsic limitations of
Jinfeng Wen, Jingtian Yu, Wuqiang Wen, Baishan Jiang   +3 more
wiley   +1 more source